For many, last week’s rescheduling announcement threw a spanner in the works. The US medical cannabis market, for now the only market to be impacted by rescheduling directly, is far smaller and, as such, much less of a priority for many operators.
Yet Acting Attorney General Todd Blanche’s announcement has done something more profound than adjust a tax position or ease a research barrier. By moving Schedule III, cannabis is officially recognised as having medical benefits for the first time.
In essence, this brings the US’ federal policy far closer to its European counterparts. The legal mechanism underpinning the rescheduling order, a provision of the Controlled Substances Act designed to bring US drug law into compliance with the 1961 UN Single Convention on Narcotic Drugs, is the same international framework that governs medical cannabis regulation across Europe.
That convergence, and what it means for operators, investors, regulators and patients on both sides of the Atlantic, is the most pressing conversation in the global cannabis industry right now, and one that will take place next month at Cannabis Europa London 2026.
This year’s edition of the Prohibition Partners flagship event will represent the first real opportunity for industry stakeholders at the heart of this convergence to examine the next phase of the industry, now that the most significant regulatory shift in cannabis policy for the last half a century is officially in place.
Returning to The Barbican in London on May 26 and 27, Cannabis Europs 2026 will bring together more than 70 speakers and over 1,000 delegates to address the full range of dynamics this new transatlantic relationship represents.
Events & Market
Europe’s medical cannabis market is projected to surpass €1.5 billion as Cannabis Europa returns to London, bringing together policymakers, investors and operators at a pivotal moment for the industry.
By Business of Cannabis • April 16, 2026
Read story →
The senior leadership teams of North America’s largest medical cannabis operators will share a stage with their European counterparts, policy makers and investors to interrogate what a world in which the US and Europe share a common medical cannabis framework actually looks like, and who is best placed to shape it.
To name just a few sessions throughout the two-day event directly addressing these themes and their wide-reaching implications, a dedicated session on UN drug policy and international law will examine whether the incremental progress of recent years is sufficient, or whether meaningful global patient access now demands a more ambitious rethink of cannabis in international law.
A more intimate fireside discussion featuring Saphira Galoob of the US Cannabis Roundtable and Bryan Lanza, a veteran of Trump’s transition team, will bring the US picture into direct focus and examine what rescheduling would and would not actually change, and what continued uncertainty means for international stakeholders watching from abroad.
With the leading voices from both sides of the Atlantic converging on Cannabis Europa next month at one of the most important moments in the history of the cannabis industry, this year’s conversations taking place at this year’s event will help shape the sector for the next decade.
The post Cannabis Europa London 2026: The First Major Gathering Since Rescheduling Changed the Game appeared first on Business of Cannabis.
Continue reading...
Yet Acting Attorney General Todd Blanche’s announcement has done something more profound than adjust a tax position or ease a research barrier. By moving Schedule III, cannabis is officially recognised as having medical benefits for the first time.
In essence, this brings the US’ federal policy far closer to its European counterparts. The legal mechanism underpinning the rescheduling order, a provision of the Controlled Substances Act designed to bring US drug law into compliance with the 1961 UN Single Convention on Narcotic Drugs, is the same international framework that governs medical cannabis regulation across Europe.
That convergence, and what it means for operators, investors, regulators and patients on both sides of the Atlantic, is the most pressing conversation in the global cannabis industry right now, and one that will take place next month at Cannabis Europa London 2026.
This year’s edition of the Prohibition Partners flagship event will represent the first real opportunity for industry stakeholders at the heart of this convergence to examine the next phase of the industry, now that the most significant regulatory shift in cannabis policy for the last half a century is officially in place.
Returning to The Barbican in London on May 26 and 27, Cannabis Europs 2026 will bring together more than 70 speakers and over 1,000 delegates to address the full range of dynamics this new transatlantic relationship represents.
Events & Market
Cannabis Europa Heads to London Amid €1.5 Billion European Market Surge
Europe’s medical cannabis market is projected to surpass €1.5 billion as Cannabis Europa returns to London, bringing together policymakers, investors and operators at a pivotal moment for the industry.
By Business of Cannabis • April 16, 2026
Read story →
The senior leadership teams of North America’s largest medical cannabis operators will share a stage with their European counterparts, policy makers and investors to interrogate what a world in which the US and Europe share a common medical cannabis framework actually looks like, and who is best placed to shape it.
To name just a few sessions throughout the two-day event directly addressing these themes and their wide-reaching implications, a dedicated session on UN drug policy and international law will examine whether the incremental progress of recent years is sufficient, or whether meaningful global patient access now demands a more ambitious rethink of cannabis in international law.
A more intimate fireside discussion featuring Saphira Galoob of the US Cannabis Roundtable and Bryan Lanza, a veteran of Trump’s transition team, will bring the US picture into direct focus and examine what rescheduling would and would not actually change, and what continued uncertainty means for international stakeholders watching from abroad.
With the leading voices from both sides of the Atlantic converging on Cannabis Europa next month at one of the most important moments in the history of the cannabis industry, this year’s conversations taking place at this year’s event will help shape the sector for the next decade.
The post Cannabis Europa London 2026: The First Major Gathering Since Rescheduling Changed the Game appeared first on Business of Cannabis.
Continue reading...
